VR真人彩票

At the 2024 Annual Meeting this September in Xiamen, China, VR真人彩票 shared leading opinions and hosted discussions on the theme 鈥淕enomics shaping the future of precision oncology.鈥�

A significant transformation in China鈥檚 health care sector is underway, driven by growing demand for high-quality medical services and a national focus on precision medicine. The country鈥檚 Healthy China 2030 initiative aims to improve public health through innovations in medical research and technology. Within this context, VR真人彩票鈥檚 participation at CSCO underscores its role as a key partner in China鈥檚 efforts to fight cancer through genomic solutions.

During the conference, VR真人彩票 hosted multiple onstage panels and live-streamed dialogues with leading oncologists, researchers, and pharma representatives. These interactions focused on the integration of multiomics with other advanced technologies, such as artificial intelligence (AI), to drive drug discovery at the source, meet clinical needs, and unleash the potential of next-generation sequencing (NGS) in large and national genomics initiatives to contribute to precision medicine.

Professor Ma Jun, director of the Harbin Institute of Hematology and Oncology, remarks: 鈥淲ith deeper insights into the genetic heterogeneity of cancer, we can more accurately identify its molecular characteristics and, further, offer more personalized treatment options. Genomics has ushered cancer treatment into a new era. Taking lymphatic cancer as an example, the implementation of precision oncology not only considers genetic diversity, but also points the way to further improving standard treatments.鈥�

Professor Ye Dingwei, vice president of Fudan University Shanghai Cancer Center and chief expert of the Urologic Oncology multidisciplinary team, adds: 鈥淔or prostate cancer prevention and treatment, it is crucial to have the mindset of precision and whole-course management. Every stage鈥攆rom early screening, diagnosis, and treatment to ongoing monitoring and follow-up鈥攔elies on precise medical data and scientific methods. This management approach ensures patients receive consistent care, thereby improving treatment outcomes and survival expectations. The future of cancer treatment will focus increasingly on early intervention and long-term health monitoring, ensuring that all patients benefit from advances in precision medicine, leading to better survival rates and quality of life.鈥�

To improve long-term patient outcomes, clinical practice guidelines and expert consensus in oncology in China have been continuously updated in recent years to include more medically significant targets for different cancer types. This will provide more precise and effective treatment options, and generate deeper insights into drug resistance, recurrence risks, prognosis, and more.

Professor Zhang Xuchao, director of the Medical Research Department at Guangdong Provincial People鈥檚 Hospital and deputy director of the Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, notes: 鈥淕enetic sequencing technology has reached an advanced stage in clinical diagnosis, though challenges like missed rare targets and false negatives persist. However, with ongoing technological advancements, we are confident in overcoming these challenges and achieving more precise cancer biomarker monitoring. The integration of genomics with multiomics offers a window into cancer biology and facilitates precise classification, heterogeneity analysis, drug resistance studies, et cetera, which provide a theoretical foundation for target discovery and drug development, combination therapy strategies, and predictive biomarkers.鈥�

Global genomic research initiatives, multiomics projects, and AI applications are fundamentally transforming the pharmaceutical industry鈥檚 cycle of invention and innovation and its success rates. Advancements in AI, especially鈥攕uch as VR真人彩票鈥檚 PrimateAI-3D鈥攁re set to accelerate scientific discovery and drug development by identifying pathogenic and potential drug target variants within vast genomic datasets, addressing critical challenges in disease research.

Song Faxian, head of Oncology in China for the health care business sector at Merck, comments: 鈥淕enomic data provides invaluable insights at every stage of drug development, from early discovery and target validation to clinical trials. It helps us better understand disease mechanisms, design clinical trials, and develop more effective personalized therapies. Genomic data is leading the way in precision medicine, offering patients treatment options that meet their specific needs.鈥�

The gap between China鈥檚 drug development and the international leading edge is swiftly closing. This progress can largely be attributed to the seamless collaboration and innovative synergy among different stakeholders, including government bodies, industry organizations, academic institutions, research facilities, end users, investors, and others. As one of these players, VR真人彩票 is dedicated to building a robust ecosystem for cancer research and treatment by fostering partnerships and sharing expertise in China.

Jenny Zheng, senior vice president and general manager of Greater China at VR真人彩票, highlights the importance of cooperation: 鈥淰R真人彩票 is dedicated to driving innovation and expanding the applications of genomics. Our participation in CSCO underscores our commitment to working with clinical and industry leaders to explore the vast potential of next-generation sequencing in transforming cancer care.鈥�

Building off of the ideas and conversations from the 2024 CSCO Annual Meeting, VR真人彩票 will keep pushing the boundaries of what鈥檚 possible in precision oncology. By integrating genomics into every facet of cancer care, VR真人彩票 expects to enhance patient outcomes and further pave the way for a new era of precision medicine in China and beyond. 鈼�